V3-mediated heparin neutralization of HIV type 1.
Javaherian
K
K
Repligen Corporation, Cambridge, Massachusetts 02139.
Khiroya
R
R
Quinlan
C
C
Boyd
J G
JG
Hanham
K A
KA
D000595:Amino Acid Sequence; D001667:Binding, Competitive; D002460:Cell Line; D003588:Cytopathogenic Effect, Viral / Q000187:drug effects; D015699:HIV Envelope Protein gp120 / Q000235:genetics / Q000378:metabolism*; D015497:HIV-1 / Q000187:drug effects* / Q000378:metabolism* / Q000472:pathogenicity; D006493:Heparin / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000235:genetics / Q000378:metabolism*
D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D010446:Peptide Fragments; D006493:Heparin